Video Experimental Relacionado
Updated: Jan 7, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
Análisis de coste-utilidad de la tecnología Control-IQ en comparación con la terapia convencional de insulina en
Jolien De Meulemeester1, Francesca Fiorentino2, Nuno Picado3
1Department of Endocrinology, University Hospitals Leuven - KU Leuven, Leuven, Belgium.
Diabetes technology & therapeutics
|December 30, 2025
Resumen
La bomba de insulina t:slim X2 con tecnología Control-IQ ofrece años de vida ajustados por calidad mejorados para pacientes con diabetes tipo 1. Este sistema automatizado de administración de insulina demuestra ser rentable desde la perspectiva de un pagador belga.
Área de la Ciencia:
- Endocrinología y Metabolismo
- Economía de la Salud
- Evaluación de Tecnologías Médicas
Sus antecedentes:
- El manejo de la diabetes tipo 1 implica equilibrar el control glucémico con la carga del tratamiento y los costes.
- Los sistemas de administración automatizada de insulina (AID), como t:slim X2 con Control-IQ, tienen como objetivo mejorar los resultados y reducir la hipoglucemia.
- Los análisis de coste-utilidad son cruciales para evaluar nuevas tecnologías médicas desde la perspectiva de un pagador de atención médica.
Objetivo del estudio:
- Evaluar la coste-utilidad de la bomba de insulina t:slim X2 con tecnología Control-IQ en comparación con inyecciones múltiples diarias (MDIs) y terapia estándar con bomba de insulina, ambas con monitorización continua de glucosa (CGM).
- Evaluar estas intervenciones desde la perspectiva de un pagador de atención médica belga.
Principales métodos:
- Análisis de coste-utilidad a lo largo de la vida utilizando el Modelo IQVIA CORE Diabetes.
- Incorporación de datos del mundo real del estudio belga INRANGE para las características basales y los efectos del tratamiento.
- Inclusión de costes médicos directos (tratamiento, complicaciones, hipoglucemia) y datos de costes específicos del país (RIZIV-INAMI).
- Valores de utilidad derivados de la literatura, teniendo en cuenta el menor temor a la hipoglucemia con Control-IQ.
Principales resultados:
- Control-IQ produjo 19,50 AVAC frente a 17,92 para MDI + CGM y bomba estándar + CGM, con costes asociados de 193.588 € y 160.129 €, respectivamente.
- La relación incremental coste-utilidad (ICUR) para Control-IQ fue de 21.111 € por AVAC ganado.
- Los análisis de escenarios confirmaron la solidez de estos hallazgos, con ICURs que oscilan entre 25.967 y 41.701 €/AVAC bajo diversas suposiciones.
Conclusiones:
- La bomba de insulina t:slim X2 con tecnología Control-IQ proporciona beneficios clínicos significativos para adultos con diabetes tipo 1 en Bélgica.
- Control-IQ parece ser una intervención rentable, lo que apoya su adopción más amplia en el manejo de la diabetes.
- Estos hallazgos tienen implicaciones para las políticas de atención médica y las decisiones de reembolso con respecto a las tecnologías avanzadas para la diabetes.
Videos de Conceptos Relacionados
01:16Insulin: Dosing Regimen and Adverse Effects
644
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
644
01:15Diabetes: Management and Pharmacotherapy
835
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
835
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
375
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
375
01:22Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
01:27Insulin Formulations: Types and Delivery
597
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
597
01:16Bioequivalence Data: Statistical Interpretation
178
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
178